Project Grant F32CA284882
Award Date
12/25/24
Completion Date
7/14/27
Dollars Obligated
$149K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $489,527 to Emory University to conduct research on understanding the functional consequences of genetic variants in the SMARCB1 gene, which is associated with certain rare and difficult-to-treat cancers affecting children, adolescents, and young adults.
The research aims to enhance the understanding of how SMARCB1 mutations impact its ability to bind to other...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $122,408 to support research conducted by President and Fellows of Harvard College to define the roles of sequence-non-specific DNA-binding domains in the assembly, function, and chromatin targeting of mammalian SWI/SNF chromatin remodeling complexes. The project aims to 1) determine how these DNA-binding domains contribute to proper SWI/SNF complex formation and enzymatic activity,...
The National Cancer Institute awarded The Johns Hopkins University a $145,642 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to support research on the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (KMT2A-R AML). The research aims to elucidate mechanisms by which HMGA1 drives leukemogenesis and therapy resistance in this aggressive form of leukemia, which is caused by rearrangements of the KMT2A gene. Specifically, the project will...
This federal Project Grant award in the amount of $113,372 was provided by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) and is focused on uncovering the molecular mechanisms and understanding the role of SERPINE family genes underlying rhabdoid tumorigenesis.
The key objectives of this 2-year award, which runs from March 1, 2025 to February 28, 2027, are to: 1) identify the molecular signatures and mechanisms underlying rhabdoid tumorigenesis in clear...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $470,000.00 to The Institute For Cancer Research to conduct mechanistic studies on genome folding and its relationship to cancer.
The key objectives are to: 1) investigate how the cohesin complex engages with chromatin during the loop extrusion process that shapes chromatin domains, 2) characterize the biochemical and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $142,310 to Duke University for a research project titled "Chromosomal Instability and 17P Loss Sensitize Cancer Cells to NDE1 Depletion." The project aims to investigate the relationship between chromosomal instability, loss of chromosome 17p, and dependence on the mitotic regulator NDE1 in cancer cells. The research will seek to characterize the role of NDE1 in proper...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $738,024 to St. Jude Children's Research Hospital Inc. to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within bromodomain PHD finger transcription factor (BPTF) in neuroblastoma. The research aims to leverage new structural biology methods to design selective inhibitors of the BPTF chromatin binding domains as...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to the Van Andel Research Institute (VAI) over 3 years (June 1, 2024 - May 31, 2027) to conduct research on oncoprotein-regulated lineage plasticity in acute leukemia. The key objectives are to: 1) Identify how KMT2A oncoproteins contribute to B-ALL to AML lineage switching events, and 2) Discover novel biomarkers and therapeutic approaches to target high-risk...
This $898,660 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research into the role of SWI/SNF chromatin remodelers in homologous recombination and genome stability. The grant is awarded under the Cancer Cause and Prevention Research program (CFDA 93.393), which supports identification of cancer risks and mechanisms for prevention.
The Midwestern University project will further define the mechanisms by which BRG1 and BRM...